Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Type 1 diabetes of at least one year duration;~2. Treated with CSII therapy for at least 6 months;~3. Age 18 to 70 years, inclusive;~4. A1C \>7.0 and ≤10% as screening;~5. BMI ≤35 kg/m2;~6. Stable insulin dose (±10%) for at least 3 months prior to screening;~7. If female, has a negative urine pregnancy test at screening;~8. If female and of childbearing potential, practicing and willing to continue to using appropriate contraception to ensure that pregnancy does not occur during the study;~9. Able to understand and sign the required study documents and comply with the protocol requirements~Exclusion Criteria:~1. Is poorly compliant with the currently prescribed insulin regimen, as determined by the investigator;~2. Has any significant medical condition, laboratory findings, or medical history that may affect successful completion of the study and/or personal well-being;~3. If female and if of childbearing potential, is pregnant, lactating, or planning to become pregnant;~4. Has experienced recurrent severe hypoglycemia requiring assistance during the past 6 months;~5. Has a history of hypoglycemia unawareness;~6. Has a confirmed diagnosis of gastroparesis;~7. Requires the use of drugs that stimulate gastrointestinal motility;~8. Is receiving medications known to interfere with glycemic control (i.e. glucocorticoids);~9. Has been treated with any oral antidiabetic agent or exenatide within 3 months of screening visit;~10. Has been treated with pramlintide within 3 months of screening visit;~11. Has received an investigational drug within 3 month of screening visit;~12. Is currently participating in a clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Interventional, continuous pramlintide infusion at 9 micrograms/hr plus 60 microgram meal bolus plus continuous insulin basal-bolus subcutaneous infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).